EQS-News

Grünenthal GmbH: Grünenthal reports record revenue and profit in 2022 full-year results and strong pipeline progress - Seite 2

"Grünenthal's exceptional performance in 2022 is a testament to our people and reflects the demand for better pain treatments," says Gabriel Baertschi, CEO and Chairman of the Corporate Executive Board. "Patients need better solutions to manage their pain as many current pain treatments do not provide sufficient relief or have severe side effects. We continue to invest in researching innovative, non-opioid pain medicines and ensure that more patients can benefit from our medicines. I am pleased with the progress towards our vision of a world free of pain."

In 2022, Grünenthal further advanced the investigational medicines in its research pipeline. A key priority is the development of Resiniferatoxin (RTX). The investigational treatment is being developed for treating pain in patients with knee osteoarthritis and entered clinical phase III in August 2022. A readout of the data is expected in the second half of 2024. The phase III programme aims to enable market authorisation in the E.U., U.S. and Japan by 2025/2026. The global osteoarthritis market has significant potential and is expected to grow to ~€11 billion in 2025. Grünenthal also has entered into an exclusive licensing agreement with Shionogi, who will obtain exclusive commercialisation rights for RTX in Japan. A partnership with NovaQuest Capital Management, a life science investment firm, further supports the development of the asset. NovaQuest shares the clinical development and approval risks with Grünenthal.

Grünenthal's second phase III programme investigates the use of Qutenza in patients with post-surgical neuropathic pain (PSNP) to support an extension of the U.S. label.

In phase I, trials are ongoing for a Nociceptin/Orphanin FQ peptide receptor (NOP) agonist. The compound is being developed to provide a non-opioid therapy option with a strong analgesic effect without the side effects commonly associated with opioids. Grünenthal also further develops its Glucocorticoid Receptor Modulator (GRM) in Phase I. The oral investigational medicine aims to provide a therapy option with broad anti-inflammatory efficacy and a more favourable benefit-risk profile than current glucocorticoid-based therapies like prednisolone.